Clinical Trial Detail

NCT ID NCT04093362
Title Futibatinib Vs Gemcitabine-Cisplatin Chemotherapy as 1st-Line Treatment of Patients With Advanced Cholangiocarcinoma (CCA) Harboring FGFR2 Gene Rearrangements (FOENIX-CCA3)
Recruitment Not yet recruiting
Gender both
Phase Phase III
Variant Requirements Yes
Sponsors Taiho Oncology, Inc.
Indications

intrahepatic cholangiocarcinoma

Therapies

Futibatinib

Cisplatin + Gemcitabine

Age Groups: adult senior

Additional content available in CKB BOOST